ELVN

Up next

Next earnings call

Apr 4, 2027 Est · unconfirmed · in 38 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 7, 2026

Equibles Rating blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 16.5 · calm Equity put/call 0.62

Technical

price trend

Strong Buy

50 / 200-day cross No cross

Price vs 200-day avg +67%

above

Price vs 50-day avg +18%

above

RSI (14) 63

neutral

MACD trend Positive

52-week position 96%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +26%

trailing

6-month return +90%

trailing

YTD return +230%

this year

Relative strength +82%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $43 › 200d $30 — 50d above 200d

Institutional flow Accumulating

8 of 174 funds reported for Jun 30 · net +344.0K sh shares · +3 new

Insider flow Distributing

Net -$52.5M over 90 days · 100% sells

Short interest Rising

14.00% of float · ▲ +57.1% MoM · 3.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

174 holders — near 3-yr high, broad support

Squeeze score 82

high risk · 0–100

Fundamentals

Strong

EPS growth +3%

Y/Y

Balance sheet $98.9M

net cash

Quant / Vol

risk profile

Very High

Volatility 81%

annualized · 1-yr

Max drawdown −37%

past year

ATR 5.3%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Buy

0 · 3 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+67% Bullish

Price vs 50-day avg

+18% Bullish

RSI (14)

63 Neutral

MACD trend

Positive Bullish

52-week position

96% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $43 › 200d $30 — 50d above 200d

Institutional flow Accumulating

8 of 174 funds reported for Jun 30 · net +344.0K sh shares · +3 new

Insider flow Distributing

Net -$52.5M over 90 days · 100% sells

Short interest Rising

14.00% of float · ▲ +57.1% MoM · 3.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

174 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $15 Now $51 · 96% 52-wk high $52

vs 200-day avg +67% vs 50-day avg +18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
cash, cash equivalents and marketable securities	$462.6M	As of December 31, 2025	—
patients enrolled in the initial cohorts of the Phase 1b trial	60	as of the cutoff date of December 22, 2025	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ELVN Enliven Therapeutics, Inc. this stock	$3.10B	+230.3%	—	—	14.0%
ONC BeOne Medicines Ltd.	$439.30B	+0.0%	+22179.2%	894.0	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$121.89B	+5.9%	+46.2%	28.5	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$69.52B	-14.0%	+20.8%	16.2	3.3%
ARGX Argenx SE	$53.71B	+4.2%	—	—	2.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

177

% held: 105.7%
Reported: 8 of 174
Top holder: ORBIMED ADVISORS LLC

Held Float

View

Held by Funds

Fund positions

172

View

Short & Settlement

Short Interest Rising

Shares short

8.5M

Days to cover: 3.1d
Change: +3.1M sh

View

Short Volume

Short vol %

72%

As of: Jul 14, 2026

Short Total

View

Fails to Deliver

FTD shares

33.1K

Value: $1.1M
As of: Jun 9, 2026

View

Off-Exchange

Off-exchange %

57.3%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$52.5M

Buyers / Sellers: 0 / 3

Buyers Sellers

View

Financials

Net income (FY)

$-103.7M

EPS diluted: $-1.83

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Jun 30, 2026
This year: 10

View

Proposed Sales

Value

$1.4M

Shares: 29.4K
Filed: Jun 22, 2026

View

Exempt Offerings

Offering

$90.0M

Filed: Apr 3, 2024

View

Earnings & Events

Earnings Calls

Last call

Jun 4, 2026

View

	5D	20D	120D	MTD	YTD
ELVN	+1.7%	+26.0%	+90.5%	+0.2%	+230.3%
SPY	-0.3%	+1.6%	+8.3%	+0.3%	+9.9%
vs SPY	+2.0%	+24.5%	+82.1%	-0.1%	+220.5%

Price & Indicators

Technicals

Key metrics

Versus peers

At a glance

Performance